Výsledky vyhledávání - "Regina Linetskaya"

Data from A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma

Autor: W. Michael Korn, Sanaa Tahiri, Regina Linetskaya, Ryan Courtin, Sharvina Ziyeh, Anna Ong, Elizabeth Dito, Alan P. Venook, R. Kate Kelley, Eric A. Collisson, Margaret A. Tempero, Peter Kuhn, AmirAli Talasaz, Nancy M. Joseph, Olga M. Mirzoeva, Jessica Van Ziffle, Tanios Bekaii-Saab, Andrew H. Ko

Purpose: On the basis of preclinical evidence of synergistic activity between MEK and EGFR inhibitors in pancreatic ductal adenocarcinoma (PDAC), we evaluated the safety and efficacy of selumetinib, a MEK1/2 inhibitor, plus erlotinib in patients with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c150d61e444e1d4c5806c0617b36149
https://doi.org/10.1158/1078-0432.c.6524340.v1

Zobrazit plný text záznamu

Supplemental figure 3 from A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma

Supplemental figure 3. Mutation frequencies in pre-and on-treatment plasma samples as determined by next-generation sequencing of cfDNA using the Guardant360 assay.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4d178c527541c3780f64e59a214d8d0
https://doi.org/10.1158/1078-0432.22459914.v1

Zobrazit plný text záznamu

Supplemental figure 1 from A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma

Supplemental figure 1. Abdominal CT scans from a patient who achieved minor response following 2 cycles of treatment. Representative sections from baseline (left) and on-treatment (right) scans are shown.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f36492a194cf605b505dc14b2c73725
https://doi.org/10.1158/1078-0432.22459920.v1

Zobrazit plný text záznamu

Supplemental figure 2 from A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma

Supplemental figure 2. Distribution of proportion of E-cadherin expressing tumor cells across all cases.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f941dd6998462a78f3a157d69c60ce1
https://doi.org/10.1158/1078-0432.22459917

Zobrazit plný text záznamu

A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma

Autor: Sanaa Tahiri, Amir Ali Talasaz, Elizabeth Dito, R. Kate Kelley, Anna Ong, W. Michael Korn, Andrew H. Ko, Ryan Courtin, Eric A. Collisson, Tanios Bekaii-Saab, Nancy M. Joseph, Regina Linetskaya, Jessica Van Ziffle, Olga M. Mirzoeva, Margaret A. Tempero, Peter Kuhn, Alan P. Venook, Sharvina Ziyeh

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research, vol 22, iss 1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fdb6a0a11a33489f81fa6895fc40168
https://doi.org/10.1158/1078-0432.ccr-15-0979

Zobrazit plný text záznamu

Abstract 5244: Next-generation sequence analysis of cell-free DNA in patients with chemotherapy-refractory advanced pancreatic adenocarcinoma (PDAC) treated with selumetinib (AZD6244) and erlotinib

Autor: Sharvina Ziyeh, Wolfgang Michael Korn, Robin Kate Kelley, Tanios Bekaii-Saab, Anna Ong, Olga K. Mirzoeva, AmirAli Talasaz, Elizabeth Ditto, Regina Linetskaya, Ryan Courtin, Alan P. Venook, Margaret A. Tempero, Andrew H. Ko

Publikováno v: Cancer Research. 75:5244-5244

Background: Monitoring molecular events in response to treatment with targeted agents is particularly challenging in pancreatic cancer due to its poor accessibility for biopsies and high stroma content. Recent advances in digital sequencing of rare D

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::54491cc9a9dde4261aac8e78bfd08adb
https://doi.org/10.1158/1538-7445.am2015-5244

Zobrazit plný text záznamu

Dual MEK/EGFR inhibition for advanced, chemotherapy-refractory pancreatic cancer: A multicenter phase II trial of selumetinib (AZD6244; ARRY-142886) plus erlotinib

Autor: Elizabeth Dito, Sharvina Ziyeh, Christina Wu, T. Bekaii-Saab, Regina Linetskaya, Robin Katie Kelley, Alan P. Venook, Anna Ong, Margaret A. Tempero, Andrew H. Ko, Peter Kuhn, Wolfgang Michael Korn, Olga K. Mirzoeva, Sanaa Tahiri, Ryan Courtin

Publikováno v: Journal of Clinical Oncology. 31:4014-4014

4014 Background: Pharmacologic inhibition of MEK leads to enhanced signaling through EGFR with hyperactivation of a parallel oncogenic pathway (PI3K) independent of mutant KRAS, supporting a therapeutic strategy of combined target inhibition in PDAC

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f1ee2802ba8ad146e9f8fd54f114b990
https://doi.org/10.1200/jco.2013.31.15_suppl.4014

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání